UPDATE: Karyopharm On Updated Selinexor Phase 1b/2 STOMP Data: SPd All Oral Regimen Shows Strong Response Rates: 55% ORR in Pomalyst-Naïve and Revlimid-Relapsed or -Refractory MM with PFS of 11.6 months; 50% ORR in the Overall Study Population
Benzinga Newsdesk